Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Payables (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Payables for 6 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 34.32% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, up 34.32%, and an annual FY2025 reading of $3.1 million, up 34.32% over the prior year.
  • Payables was $3.1 million for Q4 2025 at Xeris Biopharma Holdings, down from $6.5 million in the prior quarter.
  • Across five years, Payables topped out at $12.1 million in Q3 2023 and bottomed at $2.3 million in Q4 2024.
  • Average Payables over 5 years is $7.5 million, with a median of $6.9 million recorded in 2022.
  • The sharpest move saw Payables skyrocketed 208.43% in 2023, then crashed 80.2% in 2024.
  • Year by year, Payables stood at $8.9 million in 2021, then crashed by 48.39% to $4.6 million in 2022, then soared by 151.09% to $11.6 million in 2023, then plummeted by 80.2% to $2.3 million in 2024, then surged by 34.32% to $3.1 million in 2025.
  • Business Quant data shows Payables for XERS at $3.1 million in Q4 2025, $6.5 million in Q3 2025, and $9.5 million in Q2 2025.